Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- 3 February 2009
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 119 (1) , 33-38
Abstract
The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip®, Roche that facilitates the classification of individuals by testing 27 alleles. When patients were grouped into group 1 (*4/*4, *4/*41, *1/*5 and *2/*5) and group 2 (the remaining genotypes), a significant difference in disease-free survival (DFS) was observed between groups (P = 0.016). The mean DFS in group 1 was 95 months in contrast with 119 months in group 2. No significant relationship was found between the CYP2D6 genotype classification and severe, mild or no toxicity (P = 0.2). Nevertheless, severe, and mild toxicity was more frequent among poor metabolizer patients than in patients with a normal metabolizer pattern (18.8 and 43.8% vs. 10.7 and 36%, respectively). In breast cancer, patients treated with adjuvant tamoxifen, non-functional and severely impaired CYP2D6 variants are associated with a worse DFS and with a higher frequency of severe and mild toxicities. Larger studies of the CYP2D6 genotype-clinical outcomes association are needed to complement initial results.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Characterization of variant alleles of cytochrome CYP2D6 in a Spanish populationCell Biochemistry and Function, 2005
- Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Research and Treatment, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsBreast Cancer Research, 2005
- A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects*1Clinical Pharmacology & Therapeutics, 2004
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003
- Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O‐demethylation in different CYP2D6 genotypesBritish Journal of Clinical Pharmacology, 2000
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988